🕒 Last update: loading…

Stock UroGen Pharma Ltd. URGN

UroGen Pharma Ltd. — Investlytic score 1/5 on the five criteria.

-
-
20/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 1/5 criteria met.

  • ❌ Price trend failed
  • ⚠️ Mixed growth
  • ❌ Debt failed
  • ❌ P/E failed
  • ✅ Correction passed

Price trend

Overall trend (8 years): insufficient progression (less than x1.5).

Price change 2018 → 2019: -22.50%

Price change 2019 → 2020: -46.00%

Price change 2020 → 2021: -47.23%

Price change 2021 → 2022: -6.73%

Price change 2022 → 2023: 69.11%

Price change 2023 → 2024: -29.00%

Price change 2024 → 2025: 119.91%

Price change 2025 → 2026: 73.14%

Price change 2026 (year to date): 78.56%

Financial growth

Revenue CAGR (8 years): 92.32%

Earnings CAGR (8 years): N/A

Growth status: positive trend (>1%/yr) in revenue, earnings data insufficient/N/A.

Debt

Debt-to-equity ratio: 128332000.00

Debt/equity > 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: -20.91

P/E > 25.0 (maximum threshold).

Correction (6 months)

Current correction: 19.37% from the high over 6 months.

Correction between 10.0% and 20.0% (target range).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, mechanical verdict of the method (hold, watch, sell: the same for all) and the detail of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
UroGen Pharma Ltd.–––🔒
BioGaia AB (publ)32.70.01+13.3 %–
Clariane SE611.52.16+12.4 %–
Nutex Health, Inc.6.91.07+54.6 %–
Gerresheimer AG31.71.48+5.6 %–

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Key reported figures

Revenue, net income and net margin reported by UroGen Pharma Ltd. over the latest fiscal years.

Revenue
110 m USD
fiscal year 2025
Net income
-153 m USD
fiscal year 2025
Net margin
-139.8 %
fiscal year 2025
Average annual growth
+56.2 %
Revenue growth over 5 years
Market cap
1.3 bn USD
Fiscal yearRevenueNet incomeNet marginRevenue growth
202011.8 m-128 m-1,088.9 %n/a
202148.0 m-111 m-230.7 %+307.2 %
202264.4 m-110 m-170.6 %+34.0 %
202382.7 m-102 m-123.6 %+28.5 %
202490.4 m-127 m-140.3 %+9.3 %
2025110 m-153 m-139.8 %+21.4 %

Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.

+

Analyst consensus and forecasts

What the financial analysts covering UroGen Pharma Ltd. publish: ratings, price targets and earnings forecasts.

Majority rating
buy
16 analysts

Breakdown of ratings

strong buy 0buy 12hold 4sell 0strong sell 0

Price targets: published for companies listed in the United States only.

Track record against expectations: reported EPS above consensus 3 times over the last 12 releases.

Source: ratings and forecasts published by analysts, collected on 21/11/2026. An analyst rating or target is not a guarantee.

+

Who owns the stock

Free float, institutional investors, large funds, executives and elected officials: declared positions in UroGen Pharma Ltd.

Large funds tracked
21
hold the stock as of 2026Q2
Executives (insiders)
0 / 4
0 purchases, 4 sales in 130 days

Large funds tracked

FundSharesValue (USD)Weight in the fundChangeQuarter
BlackRock3.2 m118 m0.0 %+12.5 %2026Q2
Morgan Stanley2.6 m94.8 m0.0 %+0.6 %2026Q2
State Street2.0 m73.8 m0.0 %+129.5 %2026Q2
Point72 Asset Management1.5 m56.1 m0.1 %n/a2026Q2
D. E. Shaw & Co1.1 m42.2 m0.0 %+12.0 %2026Q2
Goldman Sachs819,83430.2 m0.0 %+37.0 %2026Q2
Geode Capital Management610,36422.5 m0.0 %+16.5 %2026Q2
Bank of America475,70217.5 m0.0 %+275.2 %2026Q2

Latest insider transactions

DatePersonSideAmount
08/10/2026Degnan Chrissale80,791 USD
08/09/2026Schoenberg Marksale37,383 USD
08/09/2026Smith Jason Drewsale64,618 USD
20/08/2026Schoenberg Marksale2.9 m USD

Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 20/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.

+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
Nasdaq
IPO: 04/05/2017
ISIN code
IL0011407140
Workforce
234
full-time employees
Chief executive
Elizabeth A. Barrett

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about UroGen Pharma Ltd.

What is the UroGen Pharma Ltd. share price?

Latest recorded price: 26.18 USD on 13/11/2026, for a market cap of 1.3 bn USD.

What is the revenue of UroGen Pharma Ltd.?

110 m USD for fiscal year 2025, with net income of -153 m USD (net margin -139.8 %).

What do analysts say about UroGen Pharma Ltd.?

Out of 16 analysts: 12 buy or strong buy, 4 hold, 0 sell or strong sell.

Is UroGen Pharma Ltd. stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN IL0011407140).

How many employees does UroGen Pharma Ltd. have?

234 full-time employees according to the latest published profile.

Who runs UroGen Pharma Ltd.?

Elizabeth A. Barrett is the company's chief executive.

Which large funds own UroGen Pharma Ltd.?

As of 2026Q2, among the large funds tracked: BlackRock, Morgan Stanley, State Street, Point72 Asset Management, D. E. Shaw & Co.

07

Similar stocks